FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2472135918> ?p ?o ?g. }

• W2472135918 endingPage "47585" @default.
• W2472135918 startingPage "47576" @default.
• W2472135918 abstract "// Jinhyuk F. Chung 1, * , Calvin J. Yoon 2, * , Seon Ah Cheon 4, * , Eun Seok Seo 2, 3 , Sung Ho Park 3 , Jae Seung Yang 5 , Bumju Kim 2 , Min Young Joo 4 , Tae Jung Park 4 , Ki Hean Kim 2 , Anil K. Sood 6 , Sang Joon Lee 2, 3 1 Synergy Point Co., Sungnam, South Korea 2 Division of Integrative Biosciences and Biotechnology (IBB), Pohang University of Science and Technology (POSTECH), Pohang, South Korea 3 Center for Biofluid and Biomimic Research, Department of Mechanical Engineering, Pohang University of Science and Technology (POSTECH), Pohang, South Korea 4 NanoBio-Chemistry Laboratory, Department of Chemistry, Chung-Ang University, Seoul, South Korea 5 Clinical Immunology, Laboratory Science Unit, International Vaccine Institute, Seoul, South Korea 6 Departments of Gynecologic Oncology and Reproductive Medicine and Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA * Co-first authors Correspondence to: Jinhyuk F. Chung, email: j.f.chung@synergypoint.co.kr Tae Jung Park, email: tjpark@cau.ac.kr Kihean Kim, email: kiheankim@postech.ac.kr Sang Joon Lee, email: sjlee@postech.ac.kr Keywords: nitric oxide, beta-blocker, heptaminol, tumor promotion, phorbol Received: May 03, 2016      Accepted: May 29, 2016      Published: June 22, 2016 ABSTRACT Recently a mouse skin carcinogenesis study reported that a β-blocker carvedilol displayed antitumor-properties via antihyperplastic effects. However, the antihyperplastic mechanism is unclear as the β-blocker is characterized with multiple pleiotropic effects including stimulation of endothelial NO release and verapamil-like calcium channel blocking activity. To investigate the nature and the origin of the antihyperplastic effects, we tested topical pretreatment with pindolol, heptaminol, ATRA or verapamil against Balb/c mouse ear skin hyperplasia that was induced by TPA. We found that pindolol, heptaminol or ATRA, but not verapamil, inhibited the TPA-induced immunoinflammatory skin changes in an NO-dependent manner, which included epidermal hyperplasia, skin edema and fibrosis. Furthermore, we also observed NO-dependent alleviation of the TPA-induced NK cell depletion in the ear tissues by heptaminol pretreatment. Together our results suggest that stimulation of NO generation from constitutive synthases may be primarily responsible for the reported antihyperplastic and NK cell-preserving effects of the β-blockers, and that similar effects may be observed in other immunity normalizing compounds that also promote endothelial NO synthesis." @default.
• W2472135918 created "2016-07-22" @default.
• W2472135918 creator A5003825516 @default.
• W2472135918 creator A5005787577 @default.
• W2472135918 creator A5009272259 @default.
• W2472135918 creator A5020081483 @default.
• W2472135918 creator A5031943603 @default.
• W2472135918 creator A5033838260 @default.
• W2472135918 creator A5047283010 @default.
• W2472135918 creator A5059995862 @default.
• W2472135918 creator A5066408904 @default.
• W2472135918 creator A5069623840 @default.
• W2472135918 creator A5073475292 @default.
• W2472135918 creator A5081145803 @default.
• W2472135918 date "2016-06-22" @default.
• W2472135918 modified "2023-10-14" @default.
• W2472135918 title "NO-dependent attenuation of TPA-induced immunoinflammatory skin changes in Balb/c mice by pindolol, heptaminol or ATRA, but not by verapamil" @default.
• W2472135918 cites W1571249274 @default.
• W2472135918 cites W1580623447 @default.
• W2472135918 cites W1647872836 @default.
• W2472135918 cites W185208703 @default.
• W2472135918 cites W1891423191 @default.
• W2472135918 cites W1947924801 @default.
• W2472135918 cites W1976377883 @default.
• W2472135918 cites W1984601093 @default.
• W2472135918 cites W1990558443 @default.
• W2472135918 cites W2008908425 @default.
• W2472135918 cites W2025080983 @default.
• W2472135918 cites W2026257886 @default.
• W2472135918 cites W2026429915 @default.
• W2472135918 cites W2028051513 @default.
• W2472135918 cites W2031937031 @default.
• W2472135918 cites W2032806869 @default.
• W2472135918 cites W2038273086 @default.
• W2472135918 cites W2044451058 @default.
• W2472135918 cites W2052974430 @default.
• W2472135918 cites W2053064871 @default.
• W2472135918 cites W2055073336 @default.
• W2472135918 cites W2060224273 @default.
• W2472135918 cites W2060266477 @default.
• W2472135918 cites W2064462205 @default.
• W2472135918 cites W2066859318 @default.
• W2472135918 cites W2068806248 @default.
• W2472135918 cites W2071340208 @default.
• W2472135918 cites W2074159903 @default.
• W2472135918 cites W2080405346 @default.
• W2472135918 cites W2085331940 @default.
• W2472135918 cites W2099279199 @default.
• W2472135918 cites W2100983001 @default.
• W2472135918 cites W2114248398 @default.
• W2472135918 cites W2124104439 @default.
• W2472135918 cites W2124303254 @default.
• W2472135918 cites W2139731996 @default.
• W2472135918 cites W2147440511 @default.
• W2472135918 cites W2150740158 @default.
• W2472135918 cites W2151840649 @default.
• W2472135918 cites W2160571820 @default.
• W2472135918 cites W2166402967 @default.
• W2472135918 cites W2169234390 @default.
• W2472135918 cites W2263721564 @default.
• W2472135918 cites W2312904549 @default.
• W2472135918 cites W4239072443 @default.
• W2472135918 cites W4313335816 @default.
• W2472135918 doi "https://doi.org/10.18632/oncotarget.10217" @default.
• W2472135918 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5216962" @default.
• W2472135918 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27374093" @default.
• W2472135918 hasPublicationYear "2016" @default.
• W2472135918 type Work @default.
• W2472135918 sameAs 2472135918 @default.
• W2472135918 citedByCount "2" @default.
• W2472135918 countsByYear W24721359182016 @default.
• W2472135918 countsByYear W24721359182017 @default.
• W2472135918 crossrefType "journal-article" @default.
• W2472135918 hasAuthorship W2472135918A5003825516 @default.
• W2472135918 hasAuthorship W2472135918A5005787577 @default.
• W2472135918 hasAuthorship W2472135918A5009272259 @default.
• W2472135918 hasAuthorship W2472135918A5020081483 @default.
• W2472135918 hasAuthorship W2472135918A5031943603 @default.
• W2472135918 hasAuthorship W2472135918A5033838260 @default.
• W2472135918 hasAuthorship W2472135918A5047283010 @default.
• W2472135918 hasAuthorship W2472135918A5059995862 @default.
• W2472135918 hasAuthorship W2472135918A5066408904 @default.
• W2472135918 hasAuthorship W2472135918A5069623840 @default.
• W2472135918 hasAuthorship W2472135918A5073475292 @default.
• W2472135918 hasAuthorship W2472135918A5081145803 @default.
• W2472135918 hasBestOaLocation W24721359181 @default.
• W2472135918 hasConcept C126322002 @default.
• W2472135918 hasConcept C185592680 @default.
• W2472135918 hasConcept C502942594 @default.
• W2472135918 hasConcept C71924100 @default.
• W2472135918 hasConcept C98274493 @default.
• W2472135918 hasConceptScore W2472135918C126322002 @default.
• W2472135918 hasConceptScore W2472135918C185592680 @default.
• W2472135918 hasConceptScore W2472135918C502942594 @default.
• W2472135918 hasConceptScore W2472135918C71924100 @default.
• W2472135918 hasConceptScore W2472135918C98274493 @default.
• W2472135918 hasIssue "30" @default.
• W2472135918 hasLocation W24721359181 @default.

• next